Drug Profile
APG 1387
Alternative Names: APG-1387; SM-1387Latest Information Update: 07 Feb 2023
Price :
$50
*
At a glance
- Originator Ascentage Pharma
- Developer Ascentage Pharma; Southern Medical University
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
- Phase I/II Adenocarcinoma; Solid tumours
- Phase I Haematological malignancies
- No development reported Lymphoma
Most Recent Events
- 30 Nov 2022 Ascentage Pharma Group completes a phase I trial in Haematological malignancies and Solid tumours (Late-stage disease) in USA (IV) (NCT03386526)
- 11 Nov 2022 APG 1387 is still in phase I trials for Hematological malignancies in USA (NCT03386526)
- 06 Nov 2022 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Chronic hepatitis B presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD-2022)